The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells (IMMUNHEMAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04805021
Recruitment Status : Recruiting
First Posted : March 18, 2021
Last Update Posted : March 21, 2024
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:

Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes drastic decrease in the level of circulating factor VIII.

This pathology occurs overwhelmingly in elderly subjects or, more rarely, in young women, during the postpartum period. It appears idiopathic in 50% of cases and associated, for the other cases, with underlying pathologies such as autoimmune pathologies (rheumatoid arthritis and bullous pemphigoid in particular) and neoplasias, or with a particular circumstance represented by the post -partum.

The association between this autoimmune pathology and its association with pathologies of the same type or with circumstances involving the immune system, suggests that common mechanisms could favor its emergence.

This study therefore proposes to study lymphocyte populations and subpopulations as well as Myeloid-Derived Suppressor Cells and the cytokine profile, which are abnormal in a large part of autoimmune pathologies.


Condition or disease Intervention/treatment
Hemophilia A Other: no intervention

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
Actual Study Start Date : November 30, 2021
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2025


Group/Cohort Intervention/treatment
Patients in the Acquired Hemophilia A group. Other: no intervention
no intervention

patients in the constitutional hemophilia A group. Other: no intervention
no intervention

patients in the control subjects group. Other: no intervention
no intervention

patients in the group of patients with inflammatory pathology. Other: no intervention
no intervention




Primary Outcome Measures :
  1. Evaluate the evolution of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines in patients with hemophilia A acquired at diagnosis and during follow-up [ Time Frame: 2 years ]
    Comparisons between diagnosis and during follow-up


Secondary Outcome Measures :
  1. To test the link between the severity of the disease at diagnosis and the cellular and cytokine parameters. [ Time Frame: 2 years ]
    Factor VIII level and inhibitor titration at diagnosis

  2. Comparisons of baseline lymphocyte and cytokine data between patients with a favorable versus unfavorable final diagnosis. [ Time Frame: 2 years ]
    Cell populations and cytokine profile and half-life of the inhibitor under treatment, time before normalization of the Factor VIII / Willebrand factor ratio, total duration of treatment with corticosteroids, recurrence and mortality tested to define a favorable course of the disease or unfavorable.

  3. Comparison of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines between different groups. [ Time Frame: 2 years ]
    Cell populations and cytokine profile of the different groups at diagnosis and at the end of follow-up.


Biospecimen Retention:   Samples Without DNA
a tube of blood taken from CTAD or citrate


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with acquired hemophilia A will be recruited prospectively when diagnosed with acquired hemophilia A and will be followed in the study until recovery.

Patients with constitutional hemophilia A will be recruited prospectively. They should be over 50 years old and have severe or moderate hemophilia A, and not be taking any treatment that could interfere with the immune system or inflammatory markers.

Population of control subjects without coagulation abnormalities, over 60 years of age and not taking any treatment likely to interfere with the immune system or inflammatory markers.

Patient population with inflammatory pathology will include subjects with an inflammatory pathology likely, according to the literature, to be associated with acquired hemophilia A and, in particular patients with rheumatoid arthritis, if possible at diagnosis and not taking any treatment likely to interfere with the disease. immune system or inflammatory markers.

Criteria

Inclusion Criteria:

  1. Patient population with acquired hemophilia A:

    Adult patients with a diagnosis of acquired hemophilia A and with a social security system. Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.

    Obtaining signed and written informed consent for biocollection consent.

  2. Population of Patients with constitutional hemophilia A:

    Adult patients over 50 years of age with severe or moderate constitutional hemophilia A, with no history of autoimmune disease, and with a social security system.

    Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.

    Obtaining signed and written informed consent for biocollection consent.

  3. Population of control subjects:

    Adult patients, over the age of 60, without a coagulation abnormality, with no history of autoimmune disease, and with a social security system.

    Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.

    Obtaining signed and written informed consent for biocollection consent.

  4. Patient population with inflammatory pathology:

Adult patients over the age of 50 with an inflammatory pathology likely to be associated with acquired hemophilia A, and with a social security system.

Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.

Obtaining signed and written informed consent for biocollection consent.

Exclusion Criteria:

For the 4 groups:

  • Minor patient, under guardianship or curatorship.
  • Pregnant and lactating women.
  • Blood transfusion less than 7 days old.
  • Treatment with corticosteroids in the 7 days preceding inclusion or any other immunomodulatory or immunosuppressive treatment in the 4 weeks preceding inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04805021


Contacts
Layout table for location contacts
Contact: Marc Fouassier 02 40 08 40 49 marc.fouassier@chu-nantes.fr

Locations
Layout table for location information
France
CHU de Nantes Recruiting
Nantes, France
Contact: Marc Fouassier    02 40 08 40 49    marc.fouassier@chu-nantes.fr   
CH de Saint Nazaire Recruiting
Saint-Nazaire, France
Contact: Julie Graveleau    0000000000    j.graveleau@ch-saintnazaire.fr   
Sponsors and Collaborators
Nantes University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Marc Fouassier Nantes University Hospital
Layout table for additonal information
Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT04805021    
Other Study ID Numbers: RC20_0253
First Posted: March 18, 2021    Key Record Dates
Last Update Posted: March 21, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn